DHR · Full Picture

DANAHER CORP /DE/ — the full picture

Earnings window · 2026-07-21 to 2026-11-09 · anchored on the 10-Q report

One earnings window, everything merged: the filing, the call, press releases and news digests, folded into ranked threads.

What to look at first

  1. Revenue Performance and Mix · Revenue growth & mixPriority 87
    -0.4% revenue; 4 sources (news, press_release, sec_filing, transcript); 4 forward row(s); structured_verified
    Since joining Danaher in 2017, Julie Sawyer Montgomery has helped grow the Diagnostics business from approximately $6.0 billion in revenue in 2017 to approximately $11.0 billion today.
  2. Guidance / Outlook · Guidance & outlookPriority 83
    +6.0% revenue; 4 sources (news, press_release, sec_filing, transcript); 14 forward row(s); quote_verified
    Management expects respiratory full-year revenue to be about $1.6 billion or a touch below that for 2026.
  3. Interest Expense Trends · Operating expenses (SG&A)Priority 80
    -55.3% operating_income; 2 sources (press_release, sec_filing); 8 forward row(s); structured_verified
    The Company estimated amortization of acquisition-related intangible assets of $0.5 billion for the third quarter and $1.9 billion for the year ending December 31, 2026.
  4. Masimo Acquisition · M&A and divestituresPriority 80
    -10.7% cash (realized); 3 sources (news, sec_filing, transcript); 4 forward row(s); structured_verified
    On June 10, 2026, the Company acquired Masimo by acquiring all of the outstanding shares of Masimo’s common stock for a cash purchase price of approximately $9.8 billion, or $180.00 per share, net of cash acquired.
  5. Liquidity and Cash Position · Liquidity & cash positionPriority 75
    +12.5% cash (realized); 1 forward row(s); structured_verified
    Total cash used in investing activities for continuing operations: $(10,696) million for nine-month period ended September 25, 2026 versus $(812) million for nine-month period ended September 26, 2025.
  6. Acquisition / Partnership / Divestiture · M&A and divestituresPriority 73
    +2.0% revenue; 3 sources (news, press_release, transcript); 6 forward row(s); quote_verified
    Leica Biosystems announced the pending acquisition of StatLab; StatLab generated approximately $250 million in revenue for the full year of 2025 and has more than 85% recurring revenue.
  7. Gross Margin Drivers · Gross marginPriority 68
    -11.4% operating_income (realized); 3 sources (news, sec_filing, transcript); structured_verified
    Gross profit for the three-month period ended June 26, 2026 was $3,611 million and cost of sales was $2,654 million, yielding a gross profit margin of 57.6%.
  8. Biotechnology Demand Trends · Demand, orders & backlogPriority 66
    -0.8% revenue; 4 sources (news, press_release, sec_filing, transcript); 1 forward row(s); quote_verified
    A market report forecasts the global research use recombinant protein market to grow from $1.11B in 2026 to $1.55B by 2031 and profiles Danaher as a key player.
  9. Competition and Market Position · Competition & market sharePriority 66
    3 sources (press_release, sec_filing, transcript); quote_verified
    Danaher said its bioprocessing portfolio was differentiated and comprehensive, positioning it to win with customers across nearly every workflow step.
  10. Operating Income and Margins · Operating income & profitabilityPriority 64
    +6.5% operating_income (realized); 3 sources (news, press_release, transcript); 2 forward row(s); quote_verified
    Adjusted operating profit margin (non-GAAP) for the three-month period ending September 25, 2026 is approximately 26.5%.
  11. Income Tax Rate Changes · TaxPriority 61
    +4.2% net_income (realized); 2 sources (press_release, sec_filing); 1 forward row(s); structured_verified
    The Company projected an effective tax rate of approximately 17.0% for the three-month period ending September 25, 2026 and for the year ending December 31, 2026.
  12. Operating Cash Flow and Capex · Capital expenditurePriority 61
    +10.5% net_income (realized); structured_verified
    Operating cash flows were approximately $4.7 billion for the first nine months of 2026, an increase of $443 million, or 10%, compared to the comparable period of 2025.

Threads by pillar

Revenue & Demand Priority 91 · 8 threads

Costs & Margins Priority 90 · 5 threads

Capital & Balance Sheet Priority 91 · 9 threads

Strategy & Portfolio Priority 85 · 5 threads

Legal, Regulatory & Policy Priority 64 · 5 threads

Guidance & Outlook Priority 83 · 1 thread

Macro & Market Conditions Priority 75 · 3 threads

Management & Governance Priority 39 · 1 thread

Unclassified Priority 78 · 5 threads

Expected impact by metric

metricforward netforward grossrealized
operating_income-55.3%+55.3%+0.4%
revenue+7.3%+14.7%+64.5%
net_income-3.4%+3.4%+24.1%
liability——-13.9%
assets——+5.4%
margin——+11.4%
cash——+5.8%